Breaking News, Collaborations & Alliances

Aurigene & Vipergen Partner to Co-Market & Offer DEL Screening Technologies to Customers

Will also co-develop new DELs with an emphasis on novel chemical diversity and drug-likeness to further strengthen their service offering.

Author Image

By: Charlie Sternberg

Associate Editor

Aurigene Pharmaceutical Services Ltd., a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DNA encoded library (DEL) technologies, have partnered to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service.   The two companies will also co-develop new DELs with an emphasis on novel chemical div...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters